Studying how the body processes polyphenols in people with type 2 diabetes
Compares polyphenol processing in adults with type 2 diabetes and adults without diabetes.
Plain-language title generated from the registry record
Registry title: Polyphenol Metabotypes in People With Diabetes Type 2
Key facts
- Where
- Ghent, BelgiumSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT06810635, who can take part
Where in Belgium
- Department of rehabilitation sciences - UGentGhent, BelgiumTaking people
- Ghent UniversityGhent, BelgiumNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Ghent
- Trial code
- NCT06810635
- Record updated
- 23 March 2026
- Original description
This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).Read full original descriptionShow less
Polyphenol Metabotypes in People With Diabetes Type 2
This cross-sectional study seeks to characterize the overall polyphenol metabotype in patients with T2DM in comparison to age-matched individuals without diabetes. Additionally, the study aims to identify factors that influence the polyphenol metabotype (transit time and gut microbial capacity to degrade polyphenols in particular).
Inclusion: all participants; between 40-85 years; age-matched individuals without diabetes; BMI between 18.5-30; no metabolic syndrome; persons with T2DM; at leats 2 years of clinical diagnoses of T2DM; stable medication use for at least 1 month.
Exclusion: start of new drug or dietary supplements; Bariatric surgery; Heart problems (NYHA 3/4) or previous cardiovascular events; Intake of coumarin derivatives and direct oral anticoagulant medication; Immonosuppressants (transplant); Antiepileptic drugs; diseases; Gastrointestinal diseases (inflammatory bowel disease); Other forms of diabetes (cystic fibrosis/MODY/T1DM); Anti-cancer treatment: chemo-/immunotherapy; pregnancy of breastfeeding; in last month; acute use of anti/pre/probiotics; major changes in diet; major lifestyle changes; Liver problems: non-alcohol steatohepatitis (NASH) and cirrhosis; Lung problems (COPD - GOLD 3/4), cystic fibrosis; Uncontrolled thyroid function disruption in the past 6 months.